Skip to main content
Premium Trial:

Request an Annual Quote

DxS: Jun 6, 2007

Manchester, UK-based DxS announced last week the launch of its K-RAS Mutation Detection Kit.
The company, in a statement, cited recently published data that suggests that in lung cancer patients K-RAS mutation status is a strong predictor of resistance to therapy with tyrosine kinase inhibitors, such as AstraZeneca’s Iressa and Roche/OSI Pharmaceuticals’ Tarceva.
“The DxS K-RAS mutation detection kit can be used to identify these patients,” DxS said. “The kit will also be used to provide valuable biomarker information to drug companies with novel therapies in development.”
The real-time PCR-based kit detects seven key mutations in the K-RAS gene. The assays can detect less than 1 percent of mutations in wild type genomic DNA and have a limit of detection of 10 copies or below.
“The unparalleled sensitivity of the technology means that the kit detects mutations frequently missed by sequencing methods,” the company said.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.